Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors.

[1]  Roderick E. Hubbard,et al.  Current perspectives in fragment-based lead discovery (FBLD) , 2017, Essays in biochemistry.

[2]  Paul N. Mortenson,et al.  Fragment-to-Lead Medicinal Chemistry Publications in 2016. , 2017, Journal of medicinal chemistry.

[3]  Robert Gustafsson,et al.  Fragment-Based Discovery and Optimization of Enzyme Inhibitors by Docking of Commercial Chemical Space. , 2017, Journal of medicinal chemistry.

[4]  M. Hann,et al.  What is the future for fragment-based drug discovery? , 2017, Future medicinal chemistry.

[5]  R. Serya,et al.  Fragment‐Based Drug Discovery in the Bromodomain and Extra‐Terminal Domain Family , 2017, Archiv der Pharmazie.

[6]  Christopher W Murray,et al.  The Fragment Network: A Chemistry Recommendation Engine Built Using a Graph Database. , 2017, Journal of medicinal chemistry.

[7]  David R. Spring,et al.  A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066 , 2017, Bioorganic & medicinal chemistry.

[8]  A. Brasier,et al.  Drug Discovery Targeting Bromodomain-Containing Protein 4 , 2017, Journal of medicinal chemistry.

[9]  C. Murray,et al.  Fragment-to-Lead Medicinal Chemistry Publications in 2015. , 2017, Journal of medicinal chemistry.

[10]  Troy Z. Horvat,et al.  Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies , 2017, The Annals of pharmacotherapy.

[11]  The UniProt Consortium.  UniProt: the universal protein knowledgebase , 2016, Nucleic Acids Res..

[12]  R. Norton,et al.  The ways and means of fragment-based drug design. , 2016, Pharmacology & therapeutics.

[13]  C. Abell,et al.  Disrupting the Constitutive, Homodimeric Protein–Protein Interface in CK2β Using a Biophysical Fragment-Based Approach , 2016, Journal of the American Chemical Society.

[14]  U. H. Danielson,et al.  Biophysics in drug discovery: impact, challenges and opportunities , 2016, Nature Reviews Drug Discovery.

[15]  Qing Cao,et al.  An improved model for fragment-based lead generation at AstraZeneca. , 2016, Drug discovery today.

[16]  Stephen D Pickett,et al.  Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia. , 2016, Journal of medicinal chemistry.

[17]  Christopher W Murray,et al.  Opportunity Knocks: Organic Chemistry for Fragment-Based Drug Discovery (FBDD). , 2016, Angewandte Chemie.

[18]  Wolfgang Jahnke,et al.  Fragment-based Drug Discovery Lessons and Outlook , 2016 .

[19]  G. McGaughey,et al.  Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis. , 2015, Journal of medicinal chemistry.

[20]  S. Knapp,et al.  Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF , 2015, Journal of medicinal chemistry.

[21]  Chris Abell,et al.  Selective Targeting of the TPX2 Site of Importin-α Using Fragment-Based Ligand Design , 2015, ChemMedChem.

[22]  David J. Fallon,et al.  1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. , 2014, ACS medicinal chemistry letters.

[23]  S. Olesen,et al.  Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors , 2014, ACS chemical biology.

[24]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[25]  O. Bogatyrova,et al.  Genetic and epigenetic changes of GPX1 and GPX3 in human clear-cell renal cell carcinoma , 2013 .

[26]  O. M. Balinskyi,et al.  Geometric filters for protein-ligand complexes based on phenomenological molecular models , 2013 .

[27]  S. Knapp,et al.  PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. , 2013, Cancer research.

[28]  Daniel A Erlanson,et al.  Learning from our mistakes: the 'unknown knowns' in fragment screening. , 2013, Bioorganic & medicinal chemistry letters.

[29]  T. Blundell,et al.  Using a Fragment-Based Approach To Target Protein–Protein Interactions , 2013, Chembiochem : a European journal of chemical biology.

[30]  Monya Baker,et al.  Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.

[31]  P. Hirth,et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.

[32]  A. Gingras,et al.  Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.

[33]  S. Knapp,et al.  3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands , 2011, Journal of medicinal chemistry.

[34]  Roderick E. Hubbard,et al.  Design of a Fragment Library that maximally represents available chemical space , 2011, J. Comput. Aided Mol. Des..

[35]  James E. J. Mills,et al.  Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics , 2011, J. Comput. Aided Mol. Des..

[36]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[37]  Susan M. Boyd,et al.  Fragment library design: efficiently hunting drugs in chemical space. , 2010, Drug discovery today. Technologies.

[38]  Thomas Hesterkamp,et al.  Fragments: past, present and future. , 2010, Drug discovery today. Technologies.

[39]  M. Hahn,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[40]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[41]  Piotras Cimmperman,et al.  A quantitative model of thermal stabilization and destabilization of proteins by ligands. , 2008, Biophysical journal.

[42]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[43]  C. E. Peishoff,et al.  A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.

[44]  Daumantas Matulis,et al.  Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. , 2005, Biochemistry.

[45]  Jonathan Bard,et al.  Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. , 2004, Analytical biochemistry.

[46]  H. Berman,et al.  Electronic Reprint Biological Crystallography the Protein Data Bank Biological Crystallography the Protein Data Bank , 2022 .

[47]  Colin McMartin,et al.  QXP: Powerful, rapid computer algorithms for structure-based drug design , 1997, J. Comput. Aided Mol. Des..

[48]  Irini Akritopoulou-Zanze,et al.  Compound Collection Enhancement and Paradigms for High-Throughput Screening — an Update , 2010 .

[49]  Roderick E. Hubbard,et al.  Diffraction Structural Biology Synchrotron Radiation Fragment Approaches in Structure-based Drug Discovery , 2007 .